Lunit Cancer Screening participated in the AOCR-SGCR 2026 event in Singapore.
Public source
Publisher name
Public post
👏 That’s a wrap on an incredible AOCR-SGCR 2026 in Singapore! 👏 What an unforgettable few days connecting with the radiology community at SGCR-WIRES. Throughout the ev…
Company
Lunit Cancer Screening
- Industry
- Software Development
- Location
- Seattle, US
- Company size
- 201–500 employees
About Lunit Cancer Screening
Conquer Cancer through AI. Lunit is a public company that develops medical AI software for cancer screening and treatment. Lunit AI can empower you to enhance diagnostic performance. Our AI for chest x-ray and 2D & 3D mammography has been validated through 100+ publications in peer-reviewed journals such as JAMA Oncology, Lancet Digital Health and Radiology, and is now in use in 3,500+ sites globally. < Lunit AI Suite for Radiology > • Lunit INSIGHT CXR, AI Solution for Chest X-ray • Lunit INSIGHT MMG, AI Solution for Mammography • Lunit INSIGHT DBT, AI Solution for Digital Breast Tomosynthesis • Lunit CXR Triage, AI solution for Chest X-ray Triage *emergency department use, available in the US only *If you are interested in Lunit Oncology, please visit Lunit Oncology’s LinkedIn page.
See moreLatest activity
Latest activity from Lunit Cancer Screening
4 signals
Presence & Recognition
Lunit Cancer Screening is participating in the inaugural BRiM Summit 2026, which is scheduled for September 15–17, 2026, at The University of Western Australia.
Research & Knowledge
Lunit Cancer Screening published the latest issue of the Squeeze, which digs into evidence, context, and real-world experiences behind breast imaging conversations, including AI coworker studies, automation bias studies, AI-stream insights, and 10 considerations for a future-ready screening ecosystem.
Research & Knowledge
Lunit Cancer Screening published a study evaluating whether Lunit INSIGHT MMG correctly localized lesions in interval cancer cases.
Discover more
Similar signals
Similar public activity from other companies.
Presence & Recognition
Lunit Oncology
Lunit Oncology will present three studies at the 2026 World Conference on Lung Cancer in Seoul, showing how AI-based pathology analysis deepens understanding of the tumor microenvironment.
Presence & Recognition
Median Technologies
Median Technologies is attending the WCLC 2026 World Conference on Lung Cancer in Seoul, Republic of Korea.
Presence & Recognition
Cercare Medical
Cercare Medical participated in the presentation of Perfusion Imaging in the Angio Suite at the ESMINT Society 2026 Siemens Healthineers Symposium.
Presence & Recognition
Radformation
Radformation joined the global radiation oncology community at ESTRO meets Asia in Singapore
Presence & Recognition
HOPPR